Last reviewed 2026-04-20 · How we verify

Qvar Redihaler (BECLOMETHASONE)

Qvar Redihaler (beclomethasone) is a small molecule medication developed by Amneal Ireland Ltd and currently owned by Norton Waterford. It is approved by the FDA for the maintenance treatment of asthma and relief of acute bronchospasm. As an off-patent medication, it is available as a generic option. Qvar Redihaler works by reducing inflammation in the airways, making it easier to breathe. It is a corticosteroid that is inhaled directly into the lungs.

At a glance

Approved indications

• maintenance treatment of asthma
• relief of acute bronchospasm

Common side effects

• Oral Candidiasis
• Upper Respiratory Tract Infection
• Nasopharyngitis
• Oropharyngeal Pain
• Sinusitis
• Rhinitis Allergic
• Back Pain
• Headache
• Nausea
• Cough
• Vomiting
• Pyrexia

Key clinical trials

• Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
• Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
• Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
• Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
• Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
• Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
• Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
• Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.